Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

Chinese Microfluidics Industry 2018
Jul.2018

mapping_of_chinese_microfluidic_players_2018_yole
6 490 €

Choose a minimum of three reports from Yole Group and receive a discount of at least 36% on your package – Contact us!
+

Description

Chinese Microfluidics Industry 2018 couv flyerWill the Chinese microfluidics industry change the worldwide microfluidic landscape?

WITH AN EYE TOWARDS 2025, CHINA HAS LAUNCHED A DEEP TRANSFORMATION OF ITS INDUSTRIAL SECTOR

The Chinese government has created a strategic plan to comprehensively upgrade the country’s industrial sector and make China a major player that is independent from other countries. This plan, “Made in China 2025”, includes a focus on pharmaceuticals and medical devices. Companies involved in these sectors will benefit from almost unlimited funding by 2025, with the goal to compete with foreign industries and retake significant market share.

As a key tool for diagnostics and life sciences applications, microfluidic technology will surely benefit from this massive spend. Indeed, the chinese diagnostics market is currently dominated by large international companies like Roche and Abbott, but new Chinese companies are rising up to compete with them. The opportunity is huge for these emerging Chinese players, because the current domination of foreign players results in products that are considered too expensive and often way beyond reimbursement thresholds. Thus, Chinese players able to propose similar solutions at a lower price will seriously threaten these giants’ position in the Chinese market. We are not there yet because performance and quality still don’t meet the expectations, but the path to 2025 is long and China’s industry is improving rapidly. Moreover, demand is growing quickly: indeed, China already has the world’s largest population, one which is aging rapidly and thus needs improved care. Additionally, the end of the “one-child policy” has resulted in numerous births and an increased demand in areas such as non-invasive prenatal testing.

For all these reasons, the Chinese microfluidic market will be strongly impacted. Yole Développement (Yole)’s analysts expect that the market for microfluidic-based products sold by Chinese players will grow at a CAGR2017-2023 of 28%, from $171M in 2017 to $754.1M in 2023.

 

 Mapping of Chinese microfluidic players 2018 Yole

THE CHINESE MICROFLUIDICS INDUSTRY: A FAST-MOVING ECOSYSTEM

As a consequence of governmental support, numerous Chinese companies were recently spun-off from several universities. Starting from 2002, Government funding for microfluidic research and microfluidic companies has reached several tens of millions yuan per year, with a significant explosion in recent years. The government is also recalling Chinese executives and engineers who have worked overseas for years in order to lead these new Chinese companies and increase their chances of success. Market demand is growing, and students in microfluidics are being recruited before they even graduate.

Yole has identified 40+ Chinese companies involved in microfluidic device manufacturing and/or integration. Though a few companies (i.e. CapitalBio) have existed since the 2000s, most of these microfluidic companies have been around only a few years, and some of them already have products on the market. In fact, the timeline from company inception to product commercialization seems much shorter in China than abroad.

Today, the Chinese supply chain’s maturity is similar to what Europe and the USA’s supply chain resembled ten years ago: very few companies have full capabilities (from design and prototyping to mass manufacturing and back-end processing), and only a few projects reach mass production. However, China’s evolution should be much faster, and it won’t take the Chinese industry 10 years to catch up. The questions are: “What will be the first significant commercial success?” and “Who will be the Chinese versions of Cepheid and Abaxis, two American diagnostic companies that in the 2000s found success with microfluidic technology and were recently acquired by diagnostic giants?”

In this report, Yole’s analysts explain how China’s ecosystem may evolve over the next few years, whether foreign players can survive, and how some Chinese players are destined for big things.

 

 Chinese microfluidic landscape appear in a few years J2018 Yole

CHINESE MICROFLUIDIC COMPANIES: A THREAT TO FOREIGN PLAYERS?

Among the Chinese companies that look promising, Bohui and Micropoint are two which have full capabilities for manufacturing their microfluidic-based products, and their position is clearly to propose alternatives to the diagnostic products sold by international giants. Such companies are growing well and finding success by proposing similar solutions to the international giants, but at a much lower price. Thanks to this strategy, some Chinese companies are beginning to attract foreign customers who cannot afford similar services at Western prices. Currently, quality is still inferior to what foreign companies can offer, but this could significantly change over the next 5 - 10 years.

Globally, this is the strategy of most Chinese microfluidic players, at all levels of the supply chain: propose “good enough” products or services at a low cost, gain contracts, and grow quickly. The most obvious example is that of BGI. The genomics company has released DNA sequencers over the past three years, first in China and now worldwide. Though BGI’s technology is said to still trail the field’s gold standard (i.e. Illumina), its aggressive pricing policy allows it to rapidly gain market share and make significant progress in terms of performance. Interestingly, numerous people share the same opinion: “BGI will kill Illumina”.

It may be too early to make such a bold statement, but one thing is sure: certain Chinese companies have the potential to be a real threat to Western players, which must find solutions to contest these Asian newcomers in their respective markets, at all levels of the supply chain.

This report details the current capabilities of more than 25 Chinese microfluidic players and furnishes 30+ company profiles detailing who these players are.

 

Next generation sequencing market share in China 2018 Yole

OBJECTIVES OF THE REPORT

  • Publish a global vision of the Chinese microfluidic market, taking into account real industrial concerns along the whole supply chain, and considering Chinese and foreign players
  • Identify microfluidics applications in China and understand the associated ecosystem
  • Identify the local technologies and understand their ability to answer market needs
  • Map players at each level of the supply chain
  • Explain how Chinese players compare to Western players in terms of expertise, know-how, capabilities, and how they work together, and understand whether they can threaten Western players
  • Examine how this ecosystem might evolve
  • Provide 2016 - 2017 market data and furnish forecasts for 2017 - 2023
  • Deliver a brief overview of China’s microfluidic IP landscape
  • Provide company profiles for all identified Chinese players

 

 

Table of contents

Executive summary 10


 

Landscape overview 40


> Definitions and introduction
> Mapping of Chinese microfluidic players
> Market landscape
> Funding model
> Comparison between China and other  countries
> China’s strengths
> Why is the Chinese government supporting microfluidics?
> Poor ecosystem for system development
> Drivers for microfluidics adoption in China
> Chinese companies starting businesses abroad
> Conclusions

 

 

Patent analysis 67


 

Market data and forecasts 84


>Microfluidic-based products (volume)
> Microfluidic-based products (value)
> Microfluidic-based products - market share
> Microfluidic devices (value)
> Microfluidic-based products - chip value
> Microfluidic devices - Chinese foundries’ market share
> What tomorrow could look like

 

 

Several applications, different dynamics 94


> Applications & dynamics
> Pharma chip production

> NGS in China - market share, BGI strategy
> Some applications/technologies are expected to grow rapidly
> Foreign microfluidic companies in China
> Conclusions

 

 

Supply chain and value chain 108


> Introduction
> Microfluidic cartridge production - different models
> Repartition of Chinese players, per company type
> Microfluidic chip processing equipment
> Materials
> Players’ capabilities
> Examples of production collaborations
> Foreign players in China
> Distributors for Western players
> Other collaboration examples
> How do foundries position?
> Technical capabilities
> Chinese players working for Western companies
> Glass microfluidics - demand
> Reagent deposition capabilities
> Interactions between world regions
> Criteria for selecting a development and industrialization partner
> Value chain for point-of-need applications
> Conclusions

 

 

Examples of products and company profiles 133


 

Regulatory and market accesse 168


 

Report conlusion 177


Companies cited

3M
Abaxis
Abbott
Affymetrix
Agilent Technologies
Alere
Anatech
BaiCare
BD
Beijing Bohui Innovation Technologies
Beijing e-science
Beijing Genomics Institute (BGI Shenzhen)
Beijing Unibio
Beijing University of Technology
Berry Genomics
Biocartis
bioMérieux
Caliper Life Sciences (PerkinElmer)
CapitalBio
Celsee
Cepheid
Chinese Academy of Sciences
Chongqing University
Clearbridge Biomedics
CNRS
Corning
Coyote Biosciences
Dalian Institute of Chemical Physics
Dalian University of Technology
Daohui Biotech
Denz Bio-Medical
Digital Biosystems
Dolomite
Each-reach (Rongzhi Biotech)
Elveflow
Excbio
Fapon
Fluidigm
Fluigent
Foxgene
Fudan University
Funai Electric
Genetel Pharmaceuticals
Getein Biotech
Guangzhou Sio Optics
Harbin Institute of Technology
Harvard College
HealthDigit
Heto
Hicomp Microtech
Highland Best
Hochuen
Honeywell
HP
Huakairui
IBM
Illumina
Institute of High Energy Physics
Inzign
Jiangsu University
JIER Machine Tool Group
LabSmith
Lianer Technology
Little Things Factory
Maccura
Mesosbiosys
Micronit
Micropoint Biosciences

Micrux Technologies
Mindray
MiTASChip
MNChip
Nanoctr
NanoEntek
NanoLite Systems
Nanomed Skincare
Oxford Nanopore Technologies
Pacific Biosciences
Peking University
Philips
Prinzen Bio (Shanghai Yanzan Biotechnology)
Purui Kang
PushKang Biotechnology
Qiagen
Quanterix
Quidel
Ray Biotech
Rayme Biotech
Renji Hospital
Robert Bosch
Roche
Samsung Electronics
Schott
Sensilicon (Shanghai Central Core Electronics)
Shanghai Baio Technology
Shanghai Biochip
Shanghai Biotechnology Corporation
Shanghai Hengxin Biotechnology
Shanghai Industrial µTechnology Research Institute (SITRI)
Shanghai Jiao Tong University
Shenyang Machine Tool
SIASUN Robot & Automation
Silex Microsystems
Sinochips
Solvay
Sony
Southeast University
Superchip Technology
Suzhou Genso Optoelectronic Technology
Suzhou Hailu Biotech (Halo)
Tecnisco
Thermo Fisher Scientific
Tianjin Biochip
Tinker Bio
Tongfang Biochip
Tsinghua University
University of California
Watmind
Wenchang Chip
Wenhao Chip
Yaneng Bio
Yulong Biomedical
Zhejiang University
and more...

KEY FEATURES OF THE REPORT

  • Mapping of Chinese microfluidic players
  • Analysis of both local and foreign players’ sales and positioning in China
  • Market landscape overview
  • Comparison between China and other countries
  • Drivers for microfluidics adoption in China
  • Market data and forecasts 2017 - 2023 for microfluidic-based products and for microfluidic devices, in volume (units) and in value ($M)
  • Analysis of the dynamic applications, with a focus on next-generation sequencing
  • Supply and value chain analysis, with overview of Chinese players’ capabilities and limitations
  • Company profiles
  • First-level patent analysis